EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database

Ye Xu, Cilin Yan, Ying Zhao, Dandan Li, Mingxing Guo, Xiangli Cui iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.5655 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Ye Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Liver Failure. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Science and Technology Planning Project, Beijing Hospital Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatic failure induced by immune checkpoint inhibitors (ICIs) has been reported in only a few case series and case reports.

Objective

We aimed to explore the association between ICIs and hepatic failure and characterize the clinical features of ICI‐associated hepatic failure in the pharmacovigilance database.

Methods

Data from the first quarter (Q1) of 2015 to the fourth quarter (Q4) of 2021 in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database were retrieved for disproportionality and Bayesian analysis. Reporting odds ratios (ROR) and information component (IC) were used to evaluate correlations between ICIs and hepatic failure.

Results

Hepatic failure occurred in 0.19% (18,454/9,647,655) of all cases in the FAERS database, of which 654 cases were associated with ICIs. The overall median time from ICIs initiation to hepatic failure onset was 38 days, 72.3% of the adverse events occurred within the first 3 months, and 68.65% of the cases died after developing hepatic failure. In general, a strong signal was shown between ICIs and hepatic failure (ROR 025 = 2.70, IC 025 = 1.39). For the three categories of ICIs, programmed cell death 1 ligand 1 inhibitors (ROR 025 = 3.09, IC 025 = 1.57) had a higher risk signal than programmed cell death protein 1 inhibitors and cytotoxic T lymphocyte‐associated protein 4 inhibitors. For monotherapy, atezolizumab showed the strongest risk signal (ROR 025 = 4.07, IC 025 = 1.90). The combination of nivolumab and ipilimumab showed stronger signals of hepatic failure compared with nivolumab or ipilimumab alone (nivolumab + ipilimumab vs. ipilimumab: ROR 025 = 1.40, IC 025 = 0.16; nivolumab + ipilimumab vs. nivolumab: ROR 025 = 1.24, IC 025 = 0.34). Considering the concomitant agents used with ICIs, the majority of these regimens showed stronger signals than ICI monotherapy, such as acetaminophen (ICIs + acetaminophen vs. ICIs: ROR 025 = 1.06, IC 025 = 0.32).

Conclusions

ICIs had possible strong signals associated with hepatic failure, and most cases of hepatic failure occurred within the first 3 months and had poor outcomes, which should attract clinical attention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalLiver FailureUnited StatesHumansImmune Checkpoint InhibitorsNivolumabIpilimumabUnited States Food and Drug AdministrationBayes TheoremAcetaminophenPharmacovigilance

Stichwörter der Autor:innen

adverse event reporting systemcytotoxic T lymphocyte-associated protein 4hepatic failureimmune checkpoint inhibitorsprogrammed cell death 1 ligand 1programmed cell death protein 1

Substanzen

Immune Checkpoint InhibitorsNivolumabIpilimumabAntineoplastic Agents, ImmunologicalAcetaminophen

Autor:innen und Institutionen

  • Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • School of Pharmacy, Capital Medical University, Beijing, China.
  • School of Automation Science and Electrical Engineering, Beihang University, Beijing, China.

ORCID-Profile: Xiangli Cui

Förderung

  • Beijing Science and Technology Planning Project
  • Beijing Hospital Authority

Zitieren

APA

Xu, Y., Yan, C., Zhao, Y., Li, D., Guo, M., & Cui, X. (2023). Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database. Cancer Medicine. https://doi.org/10.1002/cam4.5655

Vancouver

Xu Y, Yan C, Zhao Y, Li D, Guo M, Cui X. Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database. Cancer Medicine. 2023. doi:10.1002/cam4.5655

BibTeX
@article{Xu2023,
  author = {Xu, Ye and Yan, Cilin and Zhao, Ying and Li, Dandan and Guo, Mingxing and Cui, Xiangli},
  title = {Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.5655}
}
Kostenlos starten →